G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
Nicholas Pena(Duke University), Laurie H. Sanders(Duke University)
Cited by 27
Related Papers
Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
|Scientific Reports|2020|43
G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage
|bioRxiv (Cold Spring Harbor Laboratory)|2022|5
Parkinson’s disease linked LRRK2 G2019S drives oxidative nuclear DNA damage and PARP1 hyperactive signaling
|bioRxiv (Cold Spring Harbor Laboratory)|2026|0
Rab12 is a regulator of mitophagy and mitochondrial homeostasis
|bioRxiv (Cold Spring Harbor Laboratory)|2026|0